In addition, using samples from untreated HCC patients, Wang et al. discovered that sorafenib was significantly less effective against CD44-positive PDOs and that blocking Hedgehog signaling significantly decreased cell viability and increased sensitivity to sorafenib. This evidence concerns the gene CD44 and hepatocellular carcinoma.